title: [Aldosterone receptor antagonists in heart failure. Rightly brought back from retirement].
abstract: There is growing evidence that aldosterone plays an important role in the development of endorgan-damage e.g. vascular and cardiac fibrosis, remodeling and endothelial dysfunction. Aldosterone-antagonism has become a novel therapeutic principle beyond its sodium retention properties in the treatment of cardiovascular diseases. In patients with severe left ventricular dysfunction spironolactone could reduce death and hospitalisation. A new selective aldosterone antagonist, eplerenone, was effective in patients with left ventricular dysfunction after myocardial infarction added to optimal medical therapy.
authors.affiliation: Medizinische Klinik, Krankenanstalten Gilead, Bielefeld. Kolloch@gilead.de
authors.forename: R
authors.initials: R
authors.lastname: Kolloch
authors.forename: E
authors.initials: E
authors.lastname: Offers
mesh_terms: D000450:Aldosterone / Q000502:physiology; D002986:Clinical Trials as Topic; D000077545:Eplerenone; D005858:Germany; D006333:Heart Failure / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology; D006801:Humans; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use*; D013148:Spironolactone / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D015996:Survival Rate; D016896:Treatment Outcome; D018487:Ventricular Dysfunction, Left / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology
chemical_list: D000451:Mineralocorticoid Receptor Antagonists; D013148:Spironolactone; D000450:Aldosterone; D000077545:Eplerenone